Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib.

Cass G G SungaMichael S HigginsRobert W RicciottiYajuan J LiuLee D Cranmer

Published in: Cancer reports (Hoboken, N.J.) (2023)

This is the third reported case of IMT associated with the novel SQSTM1::ALK fusion protein, and the second treated with alectinib. Treatment with the ALK inhibitor alectinib appears to be active in this setting.

Keyphrases

advanced non small cell lung cancer
oxidative stress
epidermal growth factor receptor
combination therapy
tyrosine kinase